The price of frontier AI capability is falling towards zero. The consequence for an IP strategy is not that AI has become cheaper. It is that anything you thought you were...
If AI collapses the cost of making your product, the question is no longer how cheaply you can make it. It is what stops a competitor making the same thing. That...
A treatment that works once and keeps working for years is a very different commercial asset from a pill taken every day. The value is created up front. It then has...
Some assets cannot be built on any timeline a budget can shorten. When that is true, the choice is no longer build, buy or licence. It is licence, or stay out....
If a capability you spent years building can be downloaded on a Sunday afternoon, the question is not how to stop that. It is what you own that survives it. Ben...
The most expensive failures in R&D are not the projects that fail. They are the projects that should never have started — and the ones that limp along because nobody had...
July was a month about ownership. Not compliance, not litigation skill – ownership. Google’s edge sits on TPU technology that competitors must come back and license. Sanofi lost the mRNA product...
Over the past two decades, US firm value flipped from mostly tangible to over 90% intangible — and the rulebook for defending those intangibles quietly rewrote itself underneath everyone. A recent...
Most AI transformations will fail for a familiar reason. Not because the strategy is wrong, but because organisations misread how change actually happens. The recent BCG analysis makes this explicit: leaders...
Most IP disputes don’t end in a clean win. They end in a split — you carry some grounds, lose others, and then discover the scoreboard the court actually cares about...
You must be logged in to post a comment.